These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32702009)

  • 1. Correction: Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
    Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
    PLoS One; 2020; 15(7):e0236916. PubMed ID: 32702009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(10):e0241430. PubMed ID: 33091069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212820. PubMed ID: 30785959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
    Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Wang D; An L; Gauba R; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
    PLoS One; 2016; 11(7):e0159895. PubMed ID: 27434074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2018; 13(11):e0207817. PubMed ID: 30440030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
    Brogna C; Coratt G; Pane M; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Bertini E; Muntoni F; Goemans N; Mercuri E;
    PLoS One; 2019; 14(7):e0220714. PubMed ID: 31365579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review.
    Valentine BA; Winand NJ; Pradhan D; Moise NS; de Lahunta A; Kornegay JN; Cooper BJ
    Am J Med Genet; 1992 Feb; 42(3):352-6. PubMed ID: 1536178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy.
    Hildyard JCW; Taylor-Brown F; Massey C; Wells DJ; Piercy RJ
    J Neuromuscul Dis; 2018; 5(2):177-191. PubMed ID: 29614692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
    Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
    PLoS One; 2018; 13(3):e0194485. PubMed ID: 29554127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan.
    Liang WC; Tian X; Yuo CY; Chen WZ; Kan TM; Su YN; Nishino I; Wong LC; Jong YJ
    PLoS One; 2017; 12(8):e0183406. PubMed ID: 28797072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-dependent attenuation of noradrenaline-induced vasoconstriction is impaired in the canine model of Duchenne muscular dystrophy.
    Kodippili K; Hakim CH; Yang HT; Pan X; Yang NN; Laughlin MH; Terjung RL; Duan D
    J Physiol; 2018 Nov; 596(21):5199-5216. PubMed ID: 30152022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: a randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
    PLOS Currents
    PLoS Curr; 2015 Mar; 7():. PubMed ID: 25821645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
    Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
    Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urological manifestations of Duchenne muscular dystrophy.
    Askeland EJ; Arlen AM; Erickson BA; Mathews KD; Cooper CS
    J Urol; 2013 Oct; 190(4 Suppl):1523-8. PubMed ID: 23357214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.
    Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D
    PLoS One; 2016; 11(1):e0147634. PubMed ID: 26799743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis between Duchenne and Becker types muscular dystrophy.
    Ishpekova B; Milanov I; Christova LG; Alexandrov AS
    Electromyogr Clin Neurophysiol; 1999; 39(5):315-8. PubMed ID: 10422002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
    Heutinck L; Kampen NV; Jansen M; Groot IJ
    J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.
    Brinkmeyer-Langford C; Balog-Alvarez C; Cai JJ; Davis BW; Kornegay JN
    BMC Genomics; 2016 Aug; 17(1):665. PubMed ID: 27549615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.